| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPN14 |
| Uniprot No | Q15678 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-189aa |
| 氨基酸序列 | MPFGLKLRRTRRYNVLSKNCFVTRIRLLDSNVIECTLSVESTGQECLEAVAQRLELRETHYFGLWFLSKSQQARWVELEKPLKKHLDKFANEPLLFFGVMFYVPNVSWLQQEATRYQYYLQVKKDVLEGRLRCTLDQVIRLAGLAVQADFGDYNQFDSQDFLREYVLFPMDLALEEAVLEELTQKVAQE |
| 预测分子量 | 29.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTPN14重组蛋白研究的参考文献及其摘要概括：
1. **文献名称**：*PTPN14 regulates the structure and dynamics of cell-cell junctions through its tyrosine phosphatase activity*
**作者**：Liu Y, et al.
**摘要**：本研究利用重组人PTPN14蛋白解析其磷酸酶结构域，发现其通过去磷酸化关键粘附分子(如β-catenin)调控细胞间连接稳定性，并揭示其在抑制上皮-间质转化(EMT)中的作用。
2. **文献名称**：*Structural basis for PTPN14 recognition by the oncoprotein YAP*
**作者**：Chen X, et al.
**摘要**：通过重组表达PTPN14的PDZ结构域，结合晶体学分析，阐明其与YAP蛋白的相互作用机制，证明该互作抑制YAP的核定位及促癌活性，为靶向Hippo通路提供依据。
3. **文献名称**：*PTPN14 deficiency promotes cancer metastasis through STAT3 pathway activation*
**作者**：Wang H, et al.
**摘要**：利用重组PTPN14蛋白进行体外磷酸化实验，发现其通过负调控STAT3磷酸化抑制肿瘤转移，并证实PTPN14低表达与乳腺癌患者预后不良相关。
注：以上文献信息为示例性内容，实际引用需核对真实出版物。
**Background of PTPN14 Recombinant Protein**
PTPN14 (Protein Tyrosine Phosphatase Non-Receptor Type 14) is a member of the protein tyrosine phosphatase (PTP) family, which plays critical roles in regulating cellular signaling by dephosphorylating tyrosine residues on target proteins. It is implicated in diverse biological processes, including cell adhesion, proliferation, and differentiation, as well as tumor suppression. Structurally, PTPN14 contains a conserved catalytic PTP domain and a FERM (Four-point-one, Ezrin, Radixin, Moesin) domain, enabling interactions with cytoskeletal components and signaling molecules such as YAP1 in the Hippo pathway. Dysregulation of PTPN14 has been linked to cancers (e.g., breast, colorectal) and developmental disorders like choanal atresia.
Recombinant PTPN14 protein is engineered for in vitro studies to investigate its enzymatic activity, substrate specificity, and molecular interactions. Produced using expression systems like *E. coli* or mammalian cells, the recombinant form often includes affinity tags (e.g., His-tag) for purification. Researchers utilize it to dissect PTPN14’s role in pathways such as Wnt/β-catenin and Hippo, explore its tumor-suppressive mechanisms, or screen for inhibitors/therapeutic agents. Its applications span cancer biology, developmental studies, and fibrosis research, providing insights into disease mechanisms and potential treatment strategies.
The availability of recombinant PTPN14 accelerates functional studies, aiding the development of targeted therapies for conditions associated with PTPN14 dysfunction.
×
